General Proximity raises $12M pre-Series A months after $16M seed
What's the deal? San Francisco biotech General ProximityDealroom has a profile for this one. Try Dealroom → has raised a $12 million pre-Series A round, backed by Daewoong PharmaceuticalDealroom has a profile for this one. Try Dealroom → and FreeMind InvestmentsDealroom has a profile for this one. Try Dealroom →. The company develops so-called induced-proximity medicines aimed at proteins long dismissed as hard to drug, across cancer, cardiometabolic disease, neurodegeneration, and longevity.
Why now? The oversubscribed round follows General Proximity's emergence from stealth in January 2025 with $16 million in seed funding led by Felicis Ventures, alongside Y Combinator, age1Dealroom has a profile for this one. Try Dealroom →, and others. The re-raise underlines steady investor appetite for its OmniTAC platform.
What's the endgame? General Proximity is building a platform rather than a single drug, an approach that creates optionality but stretches the timeline to any commercial proof point. It has stacked up external validation: non-dilutive grants from ARPA-HDealroom has a profile for this one. Try Dealroom → and the National Cancer InstituteDealroom has a profile for this one. Try Dealroom →, five big-pharma "Golden Ticket" incubator awards, and a multi-target oncology collaboration with Daiichi SankyoDealroom has a profile for this one. Try Dealroom → announced in late 2025.
What could go wrong? The company remains preclinical, with no public IND filing, human data, or lead asset. The scientific hurdles in proximity-based drug design stay formidable — from selectivity and pharmacokinetics to oral delivery and off-target effects.
The mix of venture capital, corporate money, and public funding is unusual for a preclinical biotech. Including grants and strategic capital, General Proximity has raised more than $20 million to date.
The signal: "Induced proximity" is one of the more crowded but still technically unproven corners of next-generation drug discovery. The combination of early money, blue-chip backers, and a pharma deal puts General Proximity toward the top tier of proximity-play startups — even as its own near-brush with running out of cash before its seed lead shows how much risk remains.
Read more: Noah News
Image credit: Generated with Gemini
